New EGFR Lung Cancer Drug Nears EU Approval

by | Dec 15, 2025 | Health

Spread the love
The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events than standard therapy.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments